NasdaqGS:XERS

Stock Analysis Report

Executive Summary

Xeris Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes ready-to-use injectable and infusible drug formulations.

Snowflake

Fundamentals

High growth potential with adequate balance sheet.

Risks

  • Xeris Pharmaceuticals has significant price volatility in the past 3 months.

Share Price & News

How has Xeris Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-6.8%

XERS

1.0%

US Pharmaceuticals

-0.5%

US Market


1 Year Return

-49.5%

XERS

-8.0%

US Pharmaceuticals

0.9%

US Market

XERS underperformed the Pharmaceuticals industry which returned -8.2% over the past year.

XERS underperformed the Market in United States of America which returned 0.7% over the past year.


Share holder returns

XERSIndustryMarket
7 Day-6.8%1.0%-0.5%
30 Day-7.4%3.3%4.8%
90 Day-5.7%-6.0%2.3%
1 Year-49.5%-49.5%-5.8%-8.0%3.1%0.9%
3 Yearn/a13.5%5.6%45.5%36.0%
5 Yearn/a22.3%9.3%62.5%44.7%

Price Volatility Vs. Market

How volatile is Xeris Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Xeris Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

>50%

Discount to future cash flow value


Intrinsic Value Based on Future Cash Flows

Xeris Pharmaceuticals's share price is below the future cash flow value, and at a moderate discount (> 20%).

Xeris Pharmaceuticals's share price is below the future cash flow value, and at a substantial discount (> 40%).


Price Based on Earnings

Xeris Pharmaceuticals is loss making, we can't compare its value to the US Pharmaceuticals industry average.

Xeris Pharmaceuticals is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Xeris Pharmaceuticals, we can't assess if its growth is good value.


Price Based on Value of Assets

Xeris Pharmaceuticals is overvalued based on assets compared to the US Pharmaceuticals industry average.


Next Steps

Future Growth

How is Xeris Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 4 analysts?

55.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Xeris Pharmaceuticals's revenue is expected to grow significantly at over 20% yearly.

Xeris Pharmaceuticals's earnings are expected to grow significantly at over 20% yearly.

Xeris Pharmaceuticals's revenue growth is expected to exceed the United States of America market average.

Xeris Pharmaceuticals's earnings growth is expected to exceed the United States of America market average.

Xeris Pharmaceuticals's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Xeris Pharmaceuticals will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has Xeris Pharmaceuticals performed over the past 5 years?

-128.2%

Last years earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Xeris Pharmaceuticals does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.

Unable to compare Xeris Pharmaceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Xeris Pharmaceuticals's 1-year growth to the US Pharmaceuticals industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Xeris Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Xeris Pharmaceuticals has efficiently used its assets last year compared to the US Pharmaceuticals industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Xeris Pharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Xeris Pharmaceuticals's financial position?


Financial Position Analysis

Xeris Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Xeris Pharmaceuticals's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Xeris Pharmaceuticals's level of debt (43.3%) compared to net worth is high (greater than 40%).

Unable to establish if Xeris Pharmaceuticals's debt level has increased without past 5-year debt data.


Balance Sheet

Low level of unsold assets.

Debt is covered by short term assets, assets are 3.9x debt.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Xeris Pharmaceuticals has sufficient cash runway for 1.6 years based on current free cash flow.

Xeris Pharmaceuticals has sufficient cash runway for 1.9 years if free cash flow continues to grow at historical rates of 58.6% each year.


Next Steps

Dividend

What is Xeris Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Xeris Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Xeris Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Xeris Pharmaceuticals has not reported any payouts.

Unable to verify if Xeris Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Xeris Pharmaceuticals has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Xeris Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

2.0yrs

Average management tenure


CEO

Paul Edick (63yo)

2.7yrs

Tenure

US$1,314,251

Compensation

Mr. Paul R. Edick has been the Chief Executive Officer, President and Director of Xeris Pharmaceuticals, Inc. since January 10, 2017 and has been its Chairman since June 2018. He was Chairman of the Board  ...


CEO Compensation Analysis

Paul's remuneration is about average for companies of similar size in United States of America.

Paul's compensation has been consistent with company performance over the past year, both up more than 20%.


Management Age and Tenure

2.0yrs

Average Tenure

55.5yo

Average Age

The tenure for the Xeris Pharmaceuticals management team is about average.


Board Age and Tenure

1.4yrs

Average Tenure

63yo

Average Age

The average tenure for the Xeris Pharmaceuticals board of directors is less than 3 years, this suggests a new board.


Insider Trading

No 3 month open market individual insider trading information.


Recent Insider Transactions

BuyUS$273,58512 Mar 19
Paul Edick
EntityIndividual
Role
Chief Executive Officer
President
Shares30,000
Max PriceUS$9.12
BuyUS$10,00025 Feb 19
Kenneth Johnson
EntityIndividual
Role
Senior Key Executive
Senior Vice President of Clinical Development
Shares1,000
Max PriceUS$10.00
BuyUS$50,00023 Feb 19
Barry Deutsch
EntityIndividual
Role
Chief Financial Officer
Chief Financial Officer
Shares5,000
Max PriceUS$10.00
BuyUS$25,00022 Feb 19
Beth Hecht
EntityIndividual
Role
Chief Legal Officer
Senior VP
Shares2,500
Max PriceUS$10.00
BuyUS$5,880,00021 Feb 19
Redmile Group, LLC
EntityCompany
Shares588,000
Max PriceUS$10.00
SellUS$109,25112 Feb 19
Deerfield Management Company, L.P.
EntityCompany
Shares7,241
Max PriceUS$15.11
SellUS$222,44308 Feb 19
Deerfield Management Company, L.P.
EntityCompany
Shares14,807
Max PriceUS$15.07
SellUS$106,44830 Jan 19
Deerfield Management Company, L.P.
EntityCompany
Shares7,038
Max PriceUS$15.14
SellUS$1,766,19325 Jan 19
Deerfield Management Company, L.P.
EntityCompany
Shares114,444
Max PriceUS$16.35

Ownership Breakdown


Management Team

  • Beth Hecht (55yo)

    Senior VP

    • Tenure: 0yrs
  • Paul Edick (63yo)

    President

    • Tenure: 2.7yrs
    • Compensation: US$1.31m
  • Barry Deutsch (54yo)

    Chief Financial Officer

    • Tenure: 1.4yrs
    • Compensation: US$948.18k
  • Allison Wey

    Senior Vice President of Investor Relations & Corporate Communications

    • Tenure: 1.2yrs
  • Ken Johnson (56yo)

    Senior Vice President of Clinical Development

    • Tenure: 0yrs
  • Steve Prestrelski (55yo)

    Co-Founder & Chief Scientific Officer

    • Tenure: 0yrs
  • John Shannon (57yo)

    Executive VP & COO

    • Tenure: 2.6yrs
    • Compensation: US$918.49k

Board Members

  • John Brooks (68yo)

    Scientific Advisory Board Member

    • Tenure: 0yrs
  • Orville Kolterman (71yo)

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Jeff Sherman (64yo)

    Independent Non-Executive Board Member

    • Tenure: 1.4yrs
    • Compensation: US$164.76k
  • John Schmid (56yo)

    Independent Non-Executive Board Member

    • Tenure: 2yrs
    • Compensation: US$224.75k
  • Paul Edick (63yo)

    President

    • Tenure: 2.7yrs
    • Compensation: US$1.31m
  • Ken Ward

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Marla Persky (63yo)

    Independent Non-Executive Board Member

    • Tenure: 1.4yrs
    • Compensation: US$169.26k
  • Morey Haymond

    Scientific Advisory Board Member

    • Tenure: 0yrs
  • Barbar-Jean Bormann-Kennedy (60yo)

    Independent Non-Executive Board Member

    • Tenure: 1.4yrs
    • Compensation: US$172.26k
  • Dawn Halkuff (48yo)

    Independent Non-Executive Board Member

    • Tenure: 1.4yrs
    • Compensation: US$167.76k

Company Information

Xeris Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Xeris Pharmaceuticals, Inc.
  • Ticker: XERS
  • Exchange: NasdaqGS
  • Founded: 2005
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$270.143m
  • Shares outstanding: 26.99m
  • Website: https://www.xerispharma.com

Number of Employees


Location

  • Xeris Pharmaceuticals, Inc.
  • 180 North LaSalle Street
  • Suite 1810
  • Chicago
  • Illinois
  • 60601
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
XERSNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDJun 2018
2B3DB (Deutsche Boerse AG)YesCommon StockDEEURJun 2018

Biography

Xeris Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes ready-to-use injectable and infusible drug formulations. Its proprietary XeriSol and XeriJect formulation techno ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/24 00:56
End of Day Share Price2019/09/23 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.